- Joined
- Apr 15, 2012
- Messages
- 14,792
Results: Compared with the general population, patients receiving adalimumab monotherapy did not have a greater than expected incidence of nonmelanoma skin cancer (NMSC) or other cancers, whereas those receiving combination therapy had a greater than expected incidence of malignancies other than NMSC (standardized incidence ratio, 3.04; 95% confidence interval [CI], 1.66–5.10) and of NMSC (standardized incidence ratio, 4.59; 95% CI, 2.51–7.70). Compared with patients receiving adalimumab monotherapy, those patients receiving combination therapy had an increased risk of malignancy other than NMSC (relative risk, 2.82; 95% CI, 1.07–7.44) and of NMSC (relative risk, 3.46; 95% CI, 1.08–11.06).
Conclusions: In patients with CD, the incidence of malignancy with adalimumab monotherapy was not greater than that of the general population. Co-administration of immunomodulator therapy and adalimumab was associated with an increased risk of NMSC and other cancers.
From
http://www.medscape.com/viewarticle/823003?src=wnl_edit_tpal&uac=185734DZ
Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
Mark T. Osterman, William J. Sandborn, Jean–Frederic Colombel, Anne M. Robinson, Winnie Lau, Bidan Huang, Paul F. Pollack, Roopal B. Thakkar, James D. LewisDisclosures
Gastroenterology. 2014;146(4):941-949.